Biopsy-Validated Performance of Non-Invasive Tests for Preoperative Liver Assessment in Adults with Grade II–III Obesity Undergoing Metabolic Bariatric Surgery
INTRODUCTION: Metabolic dysfunction-associated steatotic liver disease (MASLD) with advanced liver fibrosis in metabolic bariatric surgery (MBS) candidates influences perioperative risk and management. The diagnostic performance of non-invasive liver tests (NITs) remains insufficiently validated in grade II-III obesity. We aimed to evaluate biopsy-validated diagnostic performance of liver NITs in this population. METHODS: Adults with grade II-III obesity and MASLD scheduled for MBS underwent preoperative vibration controlled elastography (VCTE) with controlled attenuated parameter (CAP) (Fibroscan®, Echosens, Fr), Fibrosis-4 index (FIB-4) and Fibroscan®-AST (FAST) score calculation and systematic intraoperative liver biopsy. Diagnostic performance was evaluated using receiver operating characteristic (AUROC) curve analysis and Youden index. RESULTS: Overall, 585 participants were included (BMI 44.7 ± 5.1 kg/m²; 40.8 ± 9.6 years, 87% female). Significant (≥F2) and advanced (≥F3) liver fibrosis prevalence was 6.3% and 3.9%. FIB-4 discrimination for ≥F3 was excellent (AUROC 0.91). An optimized cut-off of 1.07 yielded 96% sensitivity and 99.8% negative predictive value. VCTE showed an AUROC of 0.89 for ≥F3 with 97.8% success rate. For fibrosis ≥F3, using the cohort-derived FIB-4 threshold of 1.07 instead of 1.30 increased the sensitivity of sequential FIB-4/VCTE testing from 65.2% to 82.6%. CAP demonstrated good accuracy for steatosis detection (AUROC 0.80). FAST score was able to rule out at risk-MASH with negative predictive value over 97%. CONCLUSIONS: In this large grade II-III obesity cohort, FIB-4 and VCTE demonstrated high accuracy for ruling out advanced fibrosis. A lower FIB-4 threshold of 1.07 improved the sensitivity of sequential FIB-4/VCTE testing; however, external validation is required before its clinical implementation. CAP and FAST provided good performance for steatosis and at-risk MASH detection. These results may support the incorporation of NITs into the routine preoperative evaluation of MBS candidates, allowing identification of patients requiring specialized hepatology care. KEY POINTS: • Large biopsy-validated severe obesity cohort undergoing MBS. • FIB-4 showed excellent negative predictive value for advanced fibrosis. • FIB-4 cut-off 1.07 improved sensitivity for advanced fibrosis diagnosis. • VCTE showed strong accuracy for ≥F2 and ≥ F3 fibrosis detection.
Authors
- Thaís Guaraná de Andrade (ORCID: https://orcid.org/0000-0003-1719-4211)
- Luís Fernando Ferreira (ORCID: https://orcid.org/0000-0002-9496-4884)
- Fernando de Barros (ORCID: https://orcid.org/0000-0002-0777-4530)
- Cristiane Valle Tovo (ORCID: https://orcid.org/0000-0002-7932-5937)
- Cristiane Alves Villela‐Nogueira (ORCID: https://orcid.org/0000-0003-1355-2368)
- Carlos Frederico Ferreira Campos (ORCID: https://orcid.org/0000-0002-2623-1160)
- Celso Didoné Filho
- Claudia Ivantes
- Leonardo Halamy
Institutions
- Universidade Federal do Rio de Janeiro (BR)
- Universidade Federal de Ciências da Saúde de Porto Alegre (BR)
- Universidade Federal Fluminense (BR)
- Hospital Nossa Senhora das Graças (BR)
Publication Details
- Journal
- Obesity Surgery
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1007/s11695-026-09051-z
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
- Universidade Federal do Rio de Janeiro